396 related articles for article (PubMed ID: 22618709)
1. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry.
Baudo F; Collins P; Huth-Kühne A; Lévesque H; Marco P; Nemes L; Pellegrini F; Tengborn L; Knoebl P;
Blood; 2012 Jul; 120(1):39-46. PubMed ID: 22618709
[TBL] [Abstract][Full Text] [Related]
2. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
Mehta DA; Oladapo AO; Epstein JD; Novack AR; Neufeld EJ; Hay JW
J Manag Care Spec Pharm; 2016 Feb; 22(2):149-57. PubMed ID: 27015254
[TBL] [Abstract][Full Text] [Related]
3. Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry.
Tengborn L; Baudo F; Huth-Kühne A; Knoebl P; Lévesque H; Marco P; Pellegrini F; Nemes L; Collins P;
BJOG; 2012 Nov; 119(12):1529-37. PubMed ID: 22901076
[TBL] [Abstract][Full Text] [Related]
4. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea.
You CW; Lee SY; Park SK
Haemophilia; 2009 Jan; 15(1):217-26. PubMed ID: 18754800
[TBL] [Abstract][Full Text] [Related]
5. Combination of FVIII and low-dose rFVIIa improves haemostasis in acquired haemophilia A patients: a collaborative controlled study.
Zhang XH; Zhu XL; Niu T; Sun J; Liu H; Feng R; Yang LH; Wei Q; Ma QH; Wang QM; Feng FE; Fu HX; Mo XD; Lv M; Huang XJ
Thromb Res; 2015 May; 135(5):835-40. PubMed ID: 25747536
[TBL] [Abstract][Full Text] [Related]
6. Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain.
Villarrubia R; Oyagüez I; Álvarez-Román MT; Mingot-Castellano ME; Parra R; Casado MA
Haemophilia; 2015 May; 21(3):320-329. PubMed ID: 25855214
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors.
Joshi AV; Stephens JM; Munro V; Mathew P; Botteman MF
Curr Med Res Opin; 2006 Jan; 22(1):23-31. PubMed ID: 16393427
[TBL] [Abstract][Full Text] [Related]
8. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors.
Iorio A; Matino D; D'Amico R; Makris M
Cochrane Database Syst Rev; 2010 Aug; (8):CD004449. PubMed ID: 20687076
[TBL] [Abstract][Full Text] [Related]
9. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic.
Salaj P; Penka M; Smejkal P; Geierova V; Ovesná P; Brabec P; Cetkovsky P; Kubes R; Mesterton J; Lindgren P
Thromb Res; 2012 May; 129(5):e233-7. PubMed ID: 22386136
[TBL] [Abstract][Full Text] [Related]
10. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
Scharrer I
Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
[TBL] [Abstract][Full Text] [Related]
11. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.
Beckman JD; Holle LA; Wolberg AS
J Thromb Haemost; 2018 Jan; 16(1):131-141. PubMed ID: 29080382
[TBL] [Abstract][Full Text] [Related]
12. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
Young G; Shafer FE; Rojas P; Seremetis S
Haemophilia; 2008 Mar; 14(2):287-94. PubMed ID: 18081834
[TBL] [Abstract][Full Text] [Related]
13. Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX.
Valentino LA; Cooper DL; Goldstein B
Haemophilia; 2011 Jul; 17(4):579-89. PubMed ID: 21294815
[TBL] [Abstract][Full Text] [Related]
14. An economic analysis of different treatments for bleeding in patients with acquired haemophilia.
Kim CH; Simmons SC; Wang D; Najafzadeh P; Azad A; Pham HP
Vox Sang; 2020 Apr; 115(3):192-199. PubMed ID: 31879973
[TBL] [Abstract][Full Text] [Related]
15. Surgery in patients with haemophilia and high responding inhibitors: Izmir experience.
Balkan C; Karapinar D; Aydogdu S; Ozcan C; Ay Y; Akin M; Kavakli K
Haemophilia; 2010 Nov; 16(6):902-9. PubMed ID: 20518817
[TBL] [Abstract][Full Text] [Related]
16. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2).
Knoebl P; Marco P; Baudo F; Collins P; Huth-Kühne A; Nemes L; Pellegrini F; Tengborn L; Lévesque H;
J Thromb Haemost; 2012 Apr; 10(4):622-31. PubMed ID: 22321904
[TBL] [Abstract][Full Text] [Related]
17. Treatment of acute bleeding in acquired haemophilia A with recombinant activated factor VII: analysis of 10-year Japanese postmarketing surveillance data.
Amano K; Seita I; Higasa S; Sawada A; Kuwahara M; Shima M
Haemophilia; 2017 Jan; 23(1):50-58. PubMed ID: 27457022
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain.
Jimenez-Yuste V; Núñez R; Romero JA; Montoro B; Espinós B
Haemophilia; 2013 Nov; 19(6):841-6. PubMed ID: 23758100
[TBL] [Abstract][Full Text] [Related]
19. Systematic monitoring of hemostatic management in hemophilia A patients with inhibitor in the perioperative period using rotational thromboelastometry.
Furukawa S; Nogami K; Ogiwara K; Yada K; Minami H; Shima M
J Thromb Haemost; 2015 Jul; 13(7):1279-84. PubMed ID: 25903848
[TBL] [Abstract][Full Text] [Related]
20. Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors.
Hay JW; Zhou ZY
Haemophilia; 2011 Sep; 17(5):e969-74. PubMed ID: 21649802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
